KR20090087135A - 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법 - Google Patents

고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법 Download PDF

Info

Publication number
KR20090087135A
KR20090087135A KR1020097015714A KR20097015714A KR20090087135A KR 20090087135 A KR20090087135 A KR 20090087135A KR 1020097015714 A KR1020097015714 A KR 1020097015714A KR 20097015714 A KR20097015714 A KR 20097015714A KR 20090087135 A KR20090087135 A KR 20090087135A
Authority
KR
South Korea
Prior art keywords
reboxetine
disorders
norepinephrine
reuptake
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097015714A
Other languages
English (en)
Korean (ko)
Inventor
에릭 에이취. 에프. 웡
사에두딘 아흐메드
로버트 클라이드 마샬
로버트 맥아더
던컨 피. 테일러
라스 버거슨
파스쿠알레 세테라
Original Assignee
파마시아 앤드 업존 캄파니 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20090087135(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 파마시아 앤드 업존 캄파니 엘엘씨 filed Critical 파마시아 앤드 업존 캄파니 엘엘씨
Publication of KR20090087135A publication Critical patent/KR20090087135A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020097015714A 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법 Ceased KR20090087135A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US14196899P 1999-07-01 1999-07-01
US60/141,968 1999-07-01
US14413199P 1999-07-16 1999-07-16
US60/144,131 1999-07-16
US15825699P 1999-10-06 1999-10-06
US60/158,256 1999-10-06
US17038199P 1999-12-13 1999-12-13
US60/170,381 1999-12-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020067017835A Division KR100935277B1 (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법

Publications (1)

Publication Number Publication Date
KR20090087135A true KR20090087135A (ko) 2009-08-14

Family

ID=27495506

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020097015714A Ceased KR20090087135A (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
KR1020017016963A Expired - Fee Related KR100704319B1 (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
KR1020057009371A Expired - Fee Related KR100717660B1 (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
KR1020097015713A Expired - Fee Related KR100948757B1 (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
KR1020067017835A Expired - Fee Related KR100935277B1 (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020017016963A Expired - Fee Related KR100704319B1 (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
KR1020057009371A Expired - Fee Related KR100717660B1 (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
KR1020097015713A Expired - Fee Related KR100948757B1 (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
KR1020067017835A Expired - Fee Related KR100935277B1 (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법

Country Status (30)

Country Link
US (18) US6465458B1 (enExample)
EP (3) EP2090312A1 (enExample)
JP (3) JP2003503450A (enExample)
KR (5) KR20090087135A (enExample)
CN (5) CN1205935C (enExample)
AR (1) AR035158A1 (enExample)
AT (9) ATE319453T1 (enExample)
AU (2) AU771258B2 (enExample)
BR (1) BR0012136A (enExample)
CA (2) CA2375908C (enExample)
CL (3) CL2008002866A1 (enExample)
CO (1) CO5190662A1 (enExample)
CZ (1) CZ299847B6 (enExample)
DE (9) DE60020613T2 (enExample)
DK (4) DK1459749T3 (enExample)
EA (6) EA006652B1 (enExample)
ES (9) ES2247572T3 (enExample)
GE (1) GEP20094798B (enExample)
HU (1) HUP0201623A3 (enExample)
IL (3) IL147246A0 (enExample)
MX (1) MXPA02000562A (enExample)
MY (1) MY137348A (enExample)
NO (4) NO20016406L (enExample)
NZ (2) NZ533243A (enExample)
PE (1) PE20010684A1 (enExample)
PL (1) PL196996B1 (enExample)
PT (5) PT1632234E (enExample)
SK (5) SK286669B6 (enExample)
TW (9) TWI298255B (enExample)
WO (1) WO2001001973A2 (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503450A (ja) * 1999-07-01 2003-01-28 ファルマシア・アンド・アップジョン・カンパニー 高選択的ノルエピネフリン再取込みインヒビターおよびその使用方法
YU37602A (sh) * 1999-12-01 2005-07-19 Ucb S.A. Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
DE60115872T2 (de) 2000-04-21 2006-07-13 Pharmacia & Upjohn Co. Llc, Kalamazoo Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom
BR0110188A (pt) * 2000-04-21 2003-03-05 Upjohn Co Compostos selecionados para o tratamento de sìndromes de fibromialgia e de fadiga crÈnica
US20040048860A1 (en) * 2000-10-31 2004-03-11 Jes Olesen Use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
CA2426069A1 (en) * 2000-11-15 2002-05-23 David Michelson Treatment of anxiety disorders
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
DE60234873D1 (de) * 2001-06-19 2010-02-04 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von affectiven Störungen
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
AU2002347984A1 (en) * 2001-11-30 2003-06-17 Eli Lilly And Company Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
DE60223718T2 (de) * 2001-12-11 2008-10-30 Eli Lilly And Co., Indianapolis Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
JP2005522445A (ja) * 2002-02-12 2005-07-28 サイプレス バイオサイエンス， インコーポレイテッド 注意欠陥過活動性障害（ａｄ／ｈｄ）の処置方法
CA2483093A1 (en) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain
CA2483464C (en) * 2002-05-17 2011-12-20 Duke University Method for treating obesity
ATE536874T1 (de) * 2002-05-30 2011-12-15 Neurosearch As Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
AU2003227755B2 (en) * 2002-06-17 2009-01-15 Pfizer Italia S.R.L. Pharmaceutical salts of reboxetine
AR040680A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
CA2495452A1 (en) * 2002-08-14 2004-02-26 Pharmacia & Upjohn Company Llc Use of reboxetine for the treatment of hot flashes
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
US7294623B2 (en) 2002-08-23 2007-11-13 Eli Lilly And Company Benzyl morpholine derivatives
EP1534291B1 (en) 2002-08-23 2008-11-12 Eli Lilly And Company 2-(phenylthiomethyl)- morpholine derivatives for use as selective norepinephrine reuptake inhibitors
AU2003284005B2 (en) * 2002-10-03 2009-12-17 Forest Laboratories Holdings Limited Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
NZ541008A (en) * 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating functional bowel disorders
NZ541009A (en) * 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating nausea, vomiting, retching or any combination thereof
AU2004227945B2 (en) * 2003-04-04 2006-10-26 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
ES2639579T3 (es) 2003-04-29 2017-10-27 Orexigen Therapeutics, Inc. Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
GB0319793D0 (en) * 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
EP1660065A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
WO2005025675A1 (en) * 2003-09-12 2005-03-24 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7550485B2 (en) 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
WO2005066144A1 (en) * 2003-12-23 2005-07-21 Eli Lilly And Company Morpholine derivatives as norepinephrine reuptake inhibitors
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
EA200601798A1 (ru) * 2004-04-30 2007-04-27 Уорнер-Ламберт Компани Ллс Замещенные соединения морфолина для лечения расстройств центральной нервной системы
KR100871272B1 (ko) * 2004-04-30 2008-11-28 화이자 인코포레이티드 모폴린 화합물
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
EP1763354A2 (en) * 2004-06-09 2007-03-21 Pfizer Limited Use of reboxetine for the treatment of pain
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20090227562A1 (en) * 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
UA86831C2 (uk) 2004-08-13 2009-05-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Композиція таблетки пролонгованого вивільнення, яка містить праміпексол або його фармацевтично прийнятну сіль, спосіб її виготовлення та її застосування
JP2008514689A (ja) * 2004-10-01 2008-05-08 ニューロキュア リミテッド Ａｄｈｄ、ｃｆｓ、ｆｍおよび鬱病の処置のためのロフェプラミンの薬学的な組成物の使用
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
DK1948155T3 (da) * 2006-06-28 2012-07-02 Chelsea Therapeutics Inc Farmaceutiske præparater omfattende droxidopa
CN101573103A (zh) 2006-11-09 2009-11-04 奥雷西根治疗公司 用于施用重量减轻药物的单位剂量包装和方法
ES2480966T3 (es) 2007-03-09 2014-07-29 Chelsea Therapeutics, Inc. Droxidopa y composición farmacéutica de la misma para el tratamiento de la fibromialgia
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
EP2152074A4 (en) * 2007-04-30 2011-07-27 Adolor Corp (-) - E-10-OH-NT COMPOSITIONS, METHODS OF SYNTHESIS AND USE
AU2008248382B2 (en) * 2007-05-07 2013-07-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20090233959A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US20090233957A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation (-)-beloxepin and methods for its synthesis and use
US8475823B2 (en) 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
JP5405571B2 (ja) 2008-07-24 2014-02-05 セラヴァンス， インコーポレーテッド ３−（フェノキシフェニルメチル）ピロリジン化合物
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2010044016A1 (en) * 2008-10-17 2010-04-22 Pfizer Limited Novel uses for esreboxetine and racemic reboxetine
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
RU2535669C2 (ru) * 2009-07-13 2014-12-20 Тереванс, Инк. 3-феноксиметилпирролидиновые соединения
JP5714580B2 (ja) 2009-07-21 2015-05-07 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ３−フェノキシメチルピロリジン化合物
KR20120124423A (ko) 2010-01-11 2012-11-13 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
WO2012051103A1 (en) 2010-10-11 2012-04-19 Theravance, Inc. Serotonin reuptake inhibitors
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
RS67076B1 (sr) 2012-06-06 2025-08-29 Nalpropion Pharmaceuticals Llc Kompozicija za upotrebu u postupku lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
EP3693020A1 (en) * 2019-02-08 2020-08-12 Burmaster International Group GmbH Potassium enriched topical formulations for pain relief and sleep aid
KR20220108122A (ko) * 2019-12-03 2022-08-02 액섬 테라퓨틱스, 인크. 신경계 장애 치료를 위한 레복세틴의 용도

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4465458A (en) * 1980-03-19 1984-08-14 Matsushita Electric Industrial Co., Ltd. Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US4596807A (en) 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
PH30083A (en) 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
US5281624A (en) 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
IL111786A0 (en) 1993-12-01 1995-01-24 Max Planck Gesellschaft Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
CZ296263B6 (cs) 1996-03-25 2006-02-15 Eli Lilly And Company Farmaceutická kompozice pro lécení bolesti a jejípouzití
AU2587297A (en) 1996-03-25 1997-10-17 Eli Lilly And Company Method for treating pain
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6572880B2 (en) * 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6479074B2 (en) * 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
WO1999011208A1 (en) 1997-08-28 1999-03-11 Williams C Donald Method and composition for transdermal administration of pharmacologic agents
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
ES2125696T3 (es) 1996-11-27 1999-03-01 Pfleger R Chem Fab Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
WO1998046227A1 (en) 1997-04-11 1998-10-22 Eli Lilly And Company Composition for treating pain
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
AU9214498A (en) 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
AU9692898A (en) 1997-10-17 1999-05-10 Eli Lilly And Company Potentiation of pharmaceuticals
CN1301164A (zh) * 1998-04-09 2001-06-27 法玛西雅厄普约翰美国公司 神经病症的新疗法
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
IT1305322B1 (it) 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
BR9909559A (pt) 1998-05-08 2000-12-19 Upjohn Co Novas combinações de drogas
SK20012000A3 (sk) 1998-06-29 2001-08-06 Pharmaceuticals Applications Asociates, Llc Transdermálny prostriedok na zmiernenie bolesti
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
JP2003503450A (ja) * 1999-07-01 2003-01-28 ファルマシア・アンド・アップジョン・カンパニー 高選択的ノルエピネフリン再取込みインヒビターおよびその使用方法
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
CN1396829A (zh) 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

Also Published As

Publication number Publication date
US6987107B2 (en) 2006-01-17
AU2004202096B2 (en) 2005-10-20
DE60022917T2 (de) 2006-06-29
US20020061910A1 (en) 2002-05-23
US6610690B2 (en) 2003-08-26
JP2006143749A (ja) 2006-06-08
NO20016406D0 (no) 2001-12-28
DE60020613D1 (de) 2005-07-07
CN1660108A (zh) 2005-08-31
EA200501496A1 (ru) 2006-06-30
EA006652B1 (ru) 2006-02-24
US6642235B2 (en) 2003-11-04
HUP0201623A2 (en) 2002-09-28
ES2258251T3 (es) 2006-08-16
CA2375908A1 (en) 2001-01-11
BR0012136A (pt) 2002-06-11
ES2247572T3 (es) 2006-03-01
ATE292971T1 (de) 2005-04-15
CN1379672A (zh) 2002-11-13
DE60019473T2 (de) 2006-02-23
MXPA02000562A (es) 2002-07-02
EA200400589A1 (ru) 2004-12-30
GEP20094798B (en) 2009-10-26
EP2087892A2 (en) 2009-08-12
US20020107249A1 (en) 2002-08-08
CN1660111A (zh) 2005-08-31
WO2001001973A8 (en) 2001-05-17
US20060135520A1 (en) 2006-06-22
DE60022917D1 (de) 2006-02-09
NO20091168L (no) 2002-02-19
ATE304358T1 (de) 2005-09-15
KR100704319B1 (ko) 2007-04-09
DK1632234T3 (da) 2007-09-17
MY137348A (en) 2009-01-30
PT1459751E (pt) 2005-11-30
ATE305788T1 (de) 2005-10-15
ATE319453T1 (de) 2006-03-15
TWI298255B (en) 2008-07-01
DE60019473D1 (de) 2005-05-19
EA008381B1 (ru) 2007-04-27
EP1196172B1 (en) 2006-03-15
PL196996B1 (pl) 2008-02-29
TW200920378A (en) 2009-05-16
SK19382001A3 (sk) 2002-07-02
US20020128173A1 (en) 2002-09-12
PT1196172E (pt) 2006-05-31
NO20091159L (no) 2002-02-19
CL2008002868A1 (es) 2009-01-09
EA200200111A1 (ru) 2002-06-27
US7241762B2 (en) 2007-07-10
WO2001001973A2 (en) 2001-01-11
TW200607511A (en) 2006-03-01
US20060128705A1 (en) 2006-06-15
AR035158A1 (es) 2004-05-05
EP2090312A1 (en) 2009-08-19
SK286669B6 (sk) 2009-03-05
DE60026704T2 (de) 2006-10-19
EP2087892A3 (en) 2009-09-30
US20060142289A1 (en) 2006-06-29
EA200700232A1 (ru) 2007-06-29
EP1196172A2 (en) 2002-04-17
PT1459750E (pt) 2005-08-31
KR20020015363A (ko) 2002-02-27
KR100935277B1 (ko) 2010-01-06
NZ515885A (en) 2004-08-27
US6703389B2 (en) 2004-03-09
KR20090087134A (ko) 2009-08-14
KR20050053799A (ko) 2005-06-08
AU5633700A (en) 2001-01-22
ES2242175T3 (es) 2005-11-01
DE60022916D1 (de) 2006-02-09
PE20010684A1 (es) 2001-06-24
ATE296634T1 (de) 2005-06-15
JP2003503450A (ja) 2003-01-28
HUP0201623A3 (en) 2004-12-28
IL187512A0 (en) 2008-06-05
US20040147614A1 (en) 2004-07-29
TWI298254B (en) 2008-07-01
ES2246487T3 (es) 2006-02-16
US20060135521A1 (en) 2006-06-22
KR100948757B1 (ko) 2010-03-23
ES2258010T3 (es) 2006-08-16
US20060264436A1 (en) 2006-11-23
NZ533243A (en) 2005-12-23
US20020086864A1 (en) 2002-07-04
US20040058925A1 (en) 2004-03-25
DE60035232D1 (de) 2007-07-26
EA200801806A1 (ru) 2008-12-30
AU771258B2 (en) 2004-03-18
DK1459749T3 (da) 2006-01-09
US20080103146A1 (en) 2008-05-01
EA011094B1 (ru) 2008-12-30
HK1076723A1 (en) 2006-01-27
TWI293250B (en) 2008-02-11
DE60022916T2 (de) 2006-07-06
US7338953B2 (en) 2008-03-04
TW200914027A (en) 2009-04-01
ES2285645T3 (es) 2007-11-16
US20030040464A1 (en) 2003-02-27
CA2375908C (en) 2006-05-30
HK1049630A1 (en) 2003-05-23
SK286104B6 (sk) 2008-03-05
DE60023043D1 (de) 2006-02-16
IL147246A0 (en) 2002-08-14
ES2246485T3 (es) 2006-02-16
TW200607510A (en) 2006-03-01
US20080103145A1 (en) 2008-05-01
DK1459750T3 (da) 2005-08-15
CL2008002867A1 (es) 2009-01-09
CO5190662A1 (es) 2002-08-29
CL2008002866A1 (es) 2009-01-09
DE60022692D1 (de) 2005-10-20
CN1660109A (zh) 2005-08-31
US7276503B2 (en) 2007-10-02
TW200607509A (en) 2006-03-01
TWI294779B (en) 2008-03-21
ES2246488T3 (es) 2006-02-16
DE60026627T2 (de) 2007-02-01
CN1660110A (zh) 2005-08-31
TW200607512A (en) 2006-03-01
DE60026627D1 (de) 2006-05-04
DK1196172T3 (da) 2006-06-19
IL187513A0 (en) 2008-06-05
NO20016406L (no) 2002-02-19
CZ299847B6 (cs) 2008-12-10
US20080096890A1 (en) 2008-04-24
ES2239311T3 (es) 2005-09-16
KR20060099544A (ko) 2006-09-19
US20080103147A1 (en) 2008-05-01
ATE305306T1 (de) 2005-10-15
DE60020613T2 (de) 2006-03-16
CA2643231A1 (en) 2001-01-11
US20090247528A1 (en) 2009-10-01
AU2004202096A1 (en) 2004-06-10
JP2006321815A (ja) 2006-11-30
KR100717660B1 (ko) 2007-05-15
EA200801805A1 (ru) 2008-12-30
DE60023043T2 (de) 2006-06-14
US6465458B1 (en) 2002-10-15
DE60035232T2 (de) 2008-02-14
EA005029B1 (ru) 2004-10-28
CN1205935C (zh) 2005-06-15
TW200407146A (en) 2004-05-16
PT1459748E (pt) 2005-08-31
TW200922594A (en) 2009-06-01
CN1289090C (zh) 2006-12-13
SK286864B6 (sk) 2009-06-05
SK286668B6 (sk) 2009-03-05
US7317011B2 (en) 2008-01-08
ATE305307T1 (de) 2005-10-15
ATE320257T1 (de) 2006-04-15
ATE364386T1 (de) 2007-07-15
PT1632234E (pt) 2007-07-09
US7723334B2 (en) 2010-05-25
DE60022692T2 (de) 2006-06-22
PL352252A1 (en) 2003-08-11
CZ20014625A3 (cs) 2002-08-14
DE60026704D1 (de) 2006-05-11
NO20091158L (no) 2002-02-19
WO2001001973A3 (en) 2002-01-17
TWI245631B (en) 2005-12-21
SK286667B6 (sk) 2009-03-05

Similar Documents

Publication Publication Date Title
KR100948757B1 (ko) 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
EP1632235A2 (en) Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders
CN1969859A (zh) 高度选择性去甲肾上腺素再摄取抑制剂及其用途
HK1103019A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
HK1076726A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
HK1089945A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
HK1076723B (en) Highly selective norepinephrine reuptake inhibitors and the use for the preparation of the medicament thereof
HK1076725A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20090727

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090826

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20091106

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20100302

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20091106

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I